ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 217

Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis

Christine McBurney1, Rohit Aggarwal2, Kevin Gibson3, Kathleen Lindell4, Carl Fuhrman5, Diane Koontz6, Frank Schneider7, Naftali Kaminski4 and Chester V. Oddis8, 1Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, 5Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, 6Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Anatomic Pathology Department, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality, Myositis, pulmonary complications, synthetase syndrome and transplantation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether myositis-associated UIP (MA-UIP) has an improved survival compared to IPF-UIP patients (pts). Our objective was to compare the cumulative and pulmonary event-free survival between MA-UIP and IPF-UIP.

 

Methods: Adult MA-UIP and IPF-UIP pts were identified using prospective registries. Pts with myositis (PM/DM/overlap) or the antisynthetase syndrome and radiographic UIP on HRCT scan (verified by a thoracic radiologist) or a lung biopsy revealing UIP histology were included. IPF pts met ATS criteria and had UIP pathology. Death status and date were verified with the Social Security Death Index. Kaplan-Meier survival curves and the log rank test compared cumulative and pulmonary event free survival (event = transplant or death) between a) all MA-UIP and IPF-UIP pts, b) MA-UIP pts with biopsy proven UIP (n=25) vs. IPF-UIP pts matched for age, gender and baseline FVC (±10%). Cox proportional hazards ratios compared overall and event free survival controlling for co-variates.

 

Results:

IPF-UIP pts (n=81) had a mean age of 63 (±8.4), 73% male, 98% Caucasian, baseline FVC% 65 (±15.3) and DLCO% 47 (±17.3).  The MA-UIP patients (n=43) had a mean age of 46 (±11.0), 35% male, 83% Caucasian, baseline FVC% 60 (±19.6) and DLCO% 47 (±18.3).

Median cumulative and event free survival time from diagnosis in IPF vs. MA-UIP was 5.2/1.8 years vs. 16.1/10.8 years, respectively. The 5 and 10 year % unadjusted event-free (graph 1) and cumulative survival was significantly worse in IPF-UIP vs. MA-UIP (25/0 vs. 80/50 and 59/32 vs. 80/65) (p < 0.001). The hazard ratio (HR) of IPF-UIP vs. MA-UIP pts was 2.86 (95% CI 1.45-5.61) for cumulative and 5.0 (95% CI 2.8-8.7) (p<0.001) for event-free survival. IPF-UIP event-free survival (but NOT cumulative survival) remained significantly worse than MA-UIP with a HR of 6.4 (95% CI 3.0-13.8) after controlling for age at ILD diagnosis, gender and baseline FVC%.

Out of 81 IPF-UIP, 36 died (mean age 68) and 45 had transplant (mean age 65) compared to 16 deaths (mean age 54) and 10 transplants (mean age of 54) in 43 MA-UIP. Respiratory failure was the most common cause of death in both groups, followed by infection.

 

25 biopsy-proven MA-UIP pts showed significantly better event free survival compared to matched IPF-UIP pts.

 

Conclusion:

MA-UIP pts demonstrated a significant survival advantage over a matched IPF cohort, suggesting that despite similar histologic and radiographic findings at presentation, the prognosis of MA-UIP is superior to that of IPF-UIP. Thus, in pts with a radiographic or pathologic UIP picture, it is critical to distinguish those with an underlying autoimmune etiology as their course and response to therapies may differ from pts with true IPF.

Graph1: Kaplan-Meier curve for event free survival of MA-UIP and IPF-UIP


Disclosure:

C. McBurney,
None;

R. Aggarwal,
None;

K. Gibson,

Consultant: Boehringer-Ingelheim biomarker program,

5;

K. Lindell,
None;

C. Fuhrman,
None;

D. Koontz,
None;

F. Schneider,
None;

N. Kaminski,
None;

C. V. Oddis,

Genetech Advisory Board,

6.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myositis-associated-usual-interstitial-pneumonia-has-better-survival-than-idiopathic-pulmonary-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology